989 related articles for article (PubMed ID: 33716040)
1. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.
Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO
J Biol Chem; 2021; 296():100536. PubMed ID: 33716040
[TBL] [Abstract][Full Text] [Related]
2. Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.
Ren W; Lan J; Ju X; Gong M; Long Q; Zhu Z; Yu Y; Wu J; Zhong J; Zhang R; Fan S; Zhong G; Huang A; Wang X; Ding Q
PLoS Pathog; 2021 Nov; 17(11):e1010053. PubMed ID: 34748603
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
Kwarteng A; Asiedu E; Sylverken AA; Larbi A; Sakyi SA; Asiedu SO
Infect Genet Evol; 2021 Jul; 91():104815. PubMed ID: 33774178
[TBL] [Abstract][Full Text] [Related]
4. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
Hoffmann M; Zhang L; Krüger N; Graichen L; Kleine-Weber H; Hofmann-Winkler H; Kempf A; Nessler S; Riggert J; Winkler MS; Schulz S; Jäck HM; Pöhlmann S
Cell Rep; 2021 Apr; 35(3):109017. PubMed ID: 33857422
[TBL] [Abstract][Full Text] [Related]
7. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis of Mink ACE2 Binding to SARS-CoV-2 and Its Mink-Derived Variants.
Su C; He J; Han P; Bai B; Li D; Cao J; Tian M; Hu Y; Zheng A; Niu S; Chen Q; Rong X; Zhang Y; Li W; Qi J; Zhao X; Yang M; Wang Q; Gao GF
J Virol; 2022 Sep; 96(17):e0081422. PubMed ID: 36000849
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
[TBL] [Abstract][Full Text] [Related]
10. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.
Gobeil SM; Janowska K; McDowell S; Mansouri K; Parks R; Stalls V; Kopp MF; Manne K; Li D; Wiehe K; Saunders KO; Edwards RJ; Korber B; Haynes BF; Henderson R; Acharya P
Science; 2021 Aug; 373(6555):. PubMed ID: 34168071
[TBL] [Abstract][Full Text] [Related]
11. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
Wu J; Nie J; Zhang L; Song H; An Y; Liang Z; Yang J; Ding R; Liu S; Li Q; Li T; Cui Z; Zhang M; He P; Wang Y; Qu X; Hu Z; Wang Q; Huang W
Signal Transduct Target Ther; 2022 Jan; 7(1):18. PubMed ID: 35046385
[TBL] [Abstract][Full Text] [Related]
12. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.
Wang R; Zhang Q; Ge J; Ren W; Zhang R; Lan J; Ju B; Su B; Yu F; Chen P; Liao H; Feng Y; Li X; Shi X; Zhang Z; Zhang F; Ding Q; Zhang T; Wang X; Zhang L
Immunity; 2021 Jul; 54(7):1611-1621.e5. PubMed ID: 34166623
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
[TBL] [Abstract][Full Text] [Related]
14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.
Xue S; Han Y; Wu F; Wang Q
Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
[TBL] [Abstract][Full Text] [Related]
17. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
19. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.
Pan T; Chen R; He X; Yuan Y; Deng X; Li R; Yan H; Yan S; Liu J; Zhang Y; Zhang X; Yu F; Zhou M; Ke C; Ma X; Zhang H
Signal Transduct Target Ther; 2021 Dec; 6(1):420. PubMed ID: 34907154
[TBL] [Abstract][Full Text] [Related]
20. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
Bayarri-Olmos R; Johnsen LB; Idorn M; Reinert LS; Rosbjerg A; Vang S; Hansen CB; Helgstrand C; Bjelke JR; Bak-Thomsen T; Paludan SR; Garred P; Skjoedt MO
Elife; 2021 Nov; 10():. PubMed ID: 34821555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
